Repurposing metformin for cancer treatment: current clinical studies

摘要: // Young Kwang Chae 1,2,3 , Ayush Arya 3 Mary-Kate Malecek Daniel Sanghoon Shin 4 Benedito Carneiro Sunandana Chandra Jason Kaplan Aparna Kalyan Jessica K. Altman Leonidas Platanias 1,2,3,5 and Francis Giles 1 Northwestern Medicine Developmental Therapeutics Institute, Chicago, IL, USA 2 Robert H. Lurie Comprehensive Cancer Center of University, University Feinberg School Medicine, David Geffen California Los Angeles, CA, 5 Division Hematology-Oncology, Department Jesse Brown VA Medical Center, Correspondence to: Chae, email: Keywords : metformin, clinical trials, cancer Received September 20, 2015 Accepted March 06, 2016 Published 19, Abstract In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical demonstrated anticancer molecular mechanisms including mTOR inhibition, cytotoxic effects, immunomodulation. Epidemiologic data decreased incidence mortality patients taking metformin. Several focused on evaluation as an agent are presently underway. Data published from small number completed trials has put forth intriguing results. Clinical pre-surgical endometrial exhibited significant decrease Ki67 with monotherapy. Another interesting observation was made breast cancer, wherein trend towards improvement proliferation markers noted without insulin resistance. survival outcomes the use is awaited. This manuscript will critically review treatment.